PD27-05 ERECTILE FUNCTION AND LOWER URINARY TRACT SYMPTOMS FOLLOWING MRI FUSION-GUIDED PROSTATE BIOPSY

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Evaluation I1 Apr 2018PD27-05 ERECTILE FUNCTION AND LOWER URINARY TRACT SYMPTOMS FOLLOWING MRI FUSION-GUIDED PROSTATE BIOPSY Ashley Shumate, Neil Sood, Colleen Thomas, and Gregory Broderick Ashley ShumateAshley Shumate More articles by this author , Neil SoodNeil Sood More articles by this author , Colleen ThomasColleen Thomas More articles by this author , and Gregory BroderickGregory Broderick More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1356AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Magnetic Resonance Imaging (MRI) fusion-guided prostate biopsy has become a widespread tool for detecting prostate cancer. There have been sporadic reports identifying men with new onset erectile dysfunction or aggravation of lower urinary tract symptoms following TRUS biopsy. We sought to evaluate the impact of MRI fusion biopsy using two validated quality of life measures: Sexual Health Inventory for Men (SHIM) and American Urologic Association (AUA) Symptom Index scores. METHODS A retrospective chart review was performed on all patients who underwent a MRI fusion-guided prostate biopsy and completed SHIM and AUA Symptom Index questionnaires between January 2014 and June 2017 at a single institution. Questionnaires were completed prior to biopsy and at 3, 6, and 12 months post-biopsy. Patients were excluded if they had no follow-up or underwent treatment for prostate cancer prior to follow-up. Post-biopsy SHIM and AUA scores were compared to pre-biopsy scores using Wilcoxon signed rank tests. Associations of PSA and number of core biopsies with change to SHIM and AUA scores was evaluated using Kendall rank correlations (Tau b). All analyses were performed using SAS (version 9.4, SAS Institute Inc., Cary NC). RESULTS A total of 247 patients underwent MRI fusion-guided prostate biopsy during the study period. Of these, 33 patients, age 53 to 76, were eligible for the study. At time of biopsy, the mean SHIM score was 19.1 and the mean AUA score was 9.6. Mean PSA prior to biopsy was 6.5 and mean number of biopsy cores taken was 14.9. There was no significant change in SHIM or AUA scores after MRI-fusion biopsy. The mean change in SHIM score from pre to post-biopsy was -0.7, -0.7, and -0.1 at 3, 6, and 12 months, respectively (p=0.14, p=0.25 and p=1, respectively). The mean change in AUA score from pre to post-biopsy was -1.5, -0.5, and -0.6 at 3, 6, and 12 months, respectively (p=0.39, p=0.97, and p=1.00, respectively). There were no significant correlations between changes in scores for the lowest post-biopsy SHIM score and either PSA (Kendall rank correlation=-0.06, p=0.66) or number of biopsy cores (Kendall rank correlation=0.23, p=0.12). There were also no significant correlations between changes in scores for the highest post-biopsy AUA score and either PSA (Kendall rank correlation=-0.08, p=0.55) or number of biopsy scores (Kendall rank correlation=-0.03, p=0.83). CONCLUSIONS Our results suggest MRI-guided fusion prostate biopsy has no effect on erectile function or lower urinary tract symptoms at 3, 6, or 12 months post-biopsy. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e558-e559 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Ashley Shumate More articles by this author Neil Sood More articles by this author Colleen Thomas More articles by this author Gregory Broderick More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...